Home / World / Psilocybin therapy appears to be at least as effective as conventional antidepressants.

Psilocybin therapy appears to be at least as effective as conventional antidepressants.



Psilocybin, the active ingredient in magic mushrooms It may be at least as effective as a serotonin reuptake inhibitor, the leading antidepressant. According to research published in New England Journal of Medicine. Phase 2, double-blind, randomized controlled trial. by comparing alsiloxibin and the antidepressant escitalopram.

“Our previous research on treatment-resistant depression and human brain scans. It clearly points to the therapeutic potential of lcelocibin. University of London researcher Robin Carhart-Harris Head of the Psychedelic Research Center at Imperial College London and founder of MyDelica said giving one-to-one alsiloxibin with a simple antidepressant felt like a bold and interesting test.

Researchers recruited 59 men and women between the ages of 1

8 and 80 with moderate to severe depression in a 6-week trial. 30 patients were randomly assigned to the psilocybin group, while the remaining patients were randomly assigned to the psilocybin group. Another 29 were assigned to the escitalopram group.

Patients in the psilocybin group received 25 mg of psilocybin between two doses. Conversely, those in the escitalopram group received only 1 mg of psilocybin during their period. which is a size that has a slight impact Patients were administered the drug in a controlled medical facility while listening to a supervised playlist. and are guided by their experiences by a psychological support team. This includes a registered psychiatrist.

Patients were also instructed to take one capsule every morning. Those in the lsiloxibin group received a placebo. while the escitalopram group received the active dose of the antidepressant.

Patients received a standardized level of depressive symptom severity, known as the Self-Reported Depression Express-List, at the start of the trial. The mean score was 14.5 out of 27 for the LSI group and 16.4 for the escitalopram group after six weeks. Scores dropped by an average of 8.0 for those in the LSI group and 6.0 for those in the escitalopram group, a statistically insignificant difference.

“Psilocybin therapy appears to be at least as effective as conventional antidepressants,” Carhart-Harris told PsyPost. And it works faster with the safety assured when given by a professional therapist.”

The researchers also found that patients in the escitalopram group were more likely to report side effects such as anxiety, dry mouth, sexual dysfunction. and decreased emotional response compared to the psilocybin group. Patients in the psilocybin group reported improved ability to cry and feel empathy, intense emotion, and happiness.

Professor Guy Goodwin, Professor Emeritus of Psychiatry at the University of Oxford. “Adjusting alsiloxibin and related drugs is the most interesting project in contemporary psychiatry. “The current study is not a quantum leap: it does not gain energy and does not prove that LSI is a better treatment than standard treatment with escitalopram for major depression. A tantalizing clue that it might be.”

Although the initial discovery was encouraging. But the study had some limitations.

Carhart-Harris explains, “Bigger trials with direct placebo conditions will help clarify and interpret our results.”

Duration of treatment may also be a factor. SSRIs such as escitalopram may take several weeks to begin reducing symptoms. “If the duration of escitalopram is extended, it is likely that patients in the escitalopram group will have better performance,” the researchers noted.

“The next big question is ‘How will lclosibin therapy be fair in large licensing trials?’ These are necessary before medical regulators can decide whether to approve LScid therapy. Is flying a licensed treatment for depression?” Carhart-Harris said.

The study, “Trial of Psilocybin vs Escitalopram for Depression,” was authored by Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe and David J. Nut.


Source link